A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors
A phase 1/2 trial of Mirvetuximab soravtansine in ovarian cancer, run by Takeda, active and no longer recruiting.
Overview
A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors is a phase 1/2 interventional study registered as NCT06390995 by Takeda, with 28 participants enrolled, started 2024-05-20 and due to reach its primary completion in 2025-04-16. Interventions recorded: TAK-853. Conditions listed: Ovarian Cancer, Solid Tumors. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer Wit
Shares Mirvetuximab soravtansine, Ovarian cancer.
- TrialA Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primar
Shares Mirvetuximab soravtansine, Ovarian cancer.
- TrialMirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ov
Shares Mirvetuximab soravtansine, Ovarian cancer.
- TrialA Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Fo
Shares Mirvetuximab soravtansine, Ovarian cancer.
- TrialA Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult
Shares Mirvetuximab soravtansine, Ovarian cancer.
- TrialMirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer
Shares Mirvetuximab soravtansine, Ovarian cancer.
- TrialMIRASOL / GOG-3045
Shares Mirvetuximab soravtansine, Ovarian cancer.
- IdeaSequence folate-receptor ADCs by payload class
Shares Mirvetuximab soravtansine, Ovarian cancer.